-
Arrowhead Reports Q1 EPS of $(0.02)
Thursday, February 10, 2011 - 5:49pm | 67Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2011 first quarter ended December 31, 2010. Revenue for the fiscal 2011 first quarter increased to $5.0 million, compared with $148,000 for the prior year period. Net loss attributable to Arrowhead for...
-
Cambrex Reports Q4 EPS of $0.18 vs. $0.10
Thursday, February 10, 2011 - 5:18pm | 58Cambrex Corporation (NYSE: CBM) reports fourth quarter results for the period ended December 31, 2010. Fourth quarter 2010 sales of $63.5 million were 8.2% higher than the fourth quarter 2009. Income from Continuing Operations for the fourth quarter 2010 was $5.2 million or $0.18 per share compared...
-
Safefty Trades Have Been Hit 02-10-2011
Thursday, February 10, 2011 - 4:49pm | 906Cusick's Corner With trade overnight mixed and disappointment from tech giant CSCO, the market looked pretty ominous until the beloved dip bid showed up. This has not returned the market to green but has lifted it off the worst levels of the session. The Claims Data on the surface looked excellent...
-
Options Brief: Sequenom, Inc. (SQNM)
Thursday, February 10, 2011 - 11:21am | 101Shares of Sequenom, Inc. (NASDAQ: SQNM) are higher on the session by 14.16%, trading at $7.66. Overall call volume is now running at 2.53x the daily average, with 11% of all calls traded being purchases on the offer. 5,254 contracts have traded on the session so far. Sequenom, Inc. is a diagnostic...
-
Wells Fargo Raises CRL Valuation Range To $44-$45 from $42-$43
Thursday, February 10, 2011 - 11:00am | 33Wells Fargo is raising its valuation range on shares of Charles River Laboratories (NYSE: CRL) to $44-$45 from $42-$43. Charles River Laboratories currently trades at $37.73.
-
Jefferies Lowers PT Of Charles River Laboratories To $35 (CRL)
Thursday, February 10, 2011 - 10:06am | 191Jefferies its out with a report lowering the Price Target of Charles River Laboratories (NYSE: CRL) due to a pessimistic EPS outlook. The report states, “CRL reported 4Q10 non-GAAP EPS of $0.60 on net revenues of $281.7M. This excludes ~$1M loss on discontinued ops (2c) and represents a lower than...
-
UPDATE: Jefferies Color On PPDI 4Q
Thursday, February 10, 2011 - 9:49am | 202Over the past year, Pharm. Product Dev. (NASDAQ: PPDI) has successfully squeezed costs while winning strategic deals, reorganizing its selling effort, and accelerating revenue growth, Jefferies reports. “CEO Grange successfully stretched the company out of its West-centric focus,” Jefferies writes...
-
Benzinga's Top Pre-Market NASDAQ Gainers (WFMI, PGNX, SQNM, XNPT)
Thursday, February 10, 2011 - 9:26am | 139Whole Foods Market Inc (NASDAQ: WFMI) rose 9.02% to $58.60 in the pre-market session. WFMI raised its 2011 projections for profit and sales. Progenics Pharmaceuticals Inc (NASDAQ: PGNX) added 8.20% to $6.20 in the pre-market session. PGNX had $58.39 million in total cash and no debt for the...
-
Jefferies Raises PT On Charles River Laboratories To $40
Thursday, February 10, 2011 - 9:09am | 28Jefferies & Company has raised the price target on Charles River Laboratories (NYSE: CRL) from $36 to $40 and maintains its Hold rating.
-
Jefferies Raises PT On Pharmaceutical Product Development To $33
Thursday, February 10, 2011 - 9:05am | 28Jefferies & Company has raised the price target on Pharmaceutical Product Development (NASDAQ: PPDI) from $32 to $33 and maintains its Buy rating.
-
pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2010: Net Loss of $0.15 Per Share
Wednesday, February 9, 2011 - 5:06pm | 88pSivida Corp. (NASDAQ: PSDV), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the product candidate ILUVIEN® for the treatment of Diabetic Macular Edema (DME), today announced financial results for its second quarter and six...
-
ILMN 4Q2010 In-Line With Preannouncement, Goldman Sachs Reports
Wednesday, February 9, 2011 - 10:27am | 109Illumina, Inc. (NASDAQ: ILMN) reported 4Q2010 revenue/EPS of $261 mn/$0.29, in-line with the 1/11 preannouncement. “This represents yoy revenue growth of 47%,” Goldman Sachs writes. “HiSeq unit production increased another 30% sequentially, positioning the company to reduce lead times as promised...
-
CRL Revenue Exceeds Jefferies Estimate By $3.6M
Wednesday, February 9, 2011 - 10:23am | 108Charles River Laboratories (NYSE: CRL) posted revenue of $281.7M “which exceed our estimate by $3.6M,” Jefferies reports. “Segment revenues were mixed with RMS posting flat YoY growth (+5.7% sequential) while PCS was down 6% YoY (up sequentially after excluding Phase I),” Jefferies writes. “RMS...
-
Benzinga's Top Downgrades (ILMN, SWIR, MOTR, USNA)
Wednesday, February 9, 2011 - 9:22am | 134Illumina Inc (NASDAQ: ILMN) was downgraded by Auriga from "buy" to "hold." ILMN's shares closed at $70.25 yesterday. Illumina's PEG ratio is 2.45. JP Morgan downgraded Sierra Wireless Inc (NASDAQ: SWIR) from "neutral" to "underweight." SWIR's shares closed at $15.50 yesterday. Sierra Wireless'...
-
Piper Jaffray Raises PT On Illumina To $76
Wednesday, February 9, 2011 - 8:50am | 27Piper Jaffray has raised the price target on Illumina, Inc. (NASDAQ: ILMN) from $61 to $76 and maintains its Overweight rating.